35 results
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices.
General legislative cost control
CORRESP
OCUP
Ocuphire Pharma Inc
7 Jul 23
Correspondence with SEC
12:00am
or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense) which … will provide other quantitative or qualitative disclosure, as appropriate, that provides more transparency as to the type of research and development expenses
UPLOAD
0u8pun13i4un
28 Jun 23
Letter from SEC
12:00am
424B5
uytlimw2 adpe
7 Jun 21
Prospectus supplement for primary offering
4:21pm
424B5
yh5qqjiawatg65hifk
11 Mar 21
Prospectus supplement for primary offering
9:19am
424B4
47b7pzk
17 Feb 21
Prospectus supplement with pricing info
7:14am
8-K/A
EX-99.3
x451u
30 Dec 20
Financial Statements and Exhibits
5:13pm
424B3
o5qy8572ja 5ta
2 Oct 20
Prospectus supplement
9:25am